MapLight Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
MapLight Therapeutics, Inc. (MPLT) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $8.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $8.63M, a 5728.38% increase year-over-year.
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $9.64M, a 4445.28% increase year-over-year.
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $125.00K, a 64.69% decline year-over-year.
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $148.00K, a 39.59% decline year-over-year.
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $36.01M, a 3233.89% increase from fiscal 2024.
- MapLight Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $1.08M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.63M 10-Q · filed 2026-08-13 | $18.26M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $9.64M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $36.01M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $125.00K 10-Q · filed 2025-12-04 | $273.00K derived: sum of 2 quarters · filed 2026-08-13 | $485.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $148.00K 10-Q · filed 2026-08-13 | $360.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $212.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $1.08M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $354.00K 10-Q · filed 2025-12-04 | $599.00K derived: sum of 2 quarters · filed 2025-12-04 | $866.00K derived: sum of 3 quarters · filed 2025-12-04 | |
| 2024-06-30 | $245.00K 10-Q · filed 2025-12-04 | $512.00K derived: sum of 2 quarters · filed 2025-12-04 | ||
| 2024-03-31 | $267.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |